Endonovo Provides Update On Variable Convertible Notes

LOS ANGELES, CA--(Marketwired - June 15, 2016) - Endonovo Therapeutics, Inc. (OTCQB: ENDV) (“Endonovo” or the “Company”), a developer of bioelectronic medicine and therapies, announced it has retired two variable conversion rate notes for $55,000 and $50,750 respectively, which the Company believes sets the stage for a new financing plan. Additionally, the Company announced it has received a temporary restraining order against Kodiak Capital, COR Clearing and BMA Securities barring their ability to trade, lend or hypothecate all the remaining shares under the Equity Purchase Agreement with Kodiak Capital, including 1.89 million freely traded shares and 215,000 “Commitment Shares” issued to Kodiak Capital.

Additionally, the Company is providing information regarding its convertible promissory note with Regal Consulting (“Regal” and the “Regal Note”), which was issued November 30, 2015 and recently disclosed in an 8-K filing. The Regal Note contains a Leak Out Provision allowing Regal to sell a maximum of 20% of the given volume in a given day and prevents Regal from making trades after 3:30 PM EST. Regal Consulting has assisted the Company with certain corporate awareness services, including management interviews, direct mail pieces to shareholders, follow up phone support with shareholders, and news articles on the Company providing significant value to shareholders.

When asked to comment, Alan Collier, the Company’s Chairman and Chief Executive Officer, stated, “As a major requirement for securing the financing required to develop our bioelectronic medicine platform, we are working with our financial advisor to retire all variable convertible notes in order to preserve shareholder value and maintain confidence in our company. The Temporary Restraining Order allows us to preserve value by removing the 1.89 million shares from our publicly traded float while we continue to position the company for a larger round of institutional financing.”

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. is an innovative biotechnology company developing bioelectronic devices and therapies for regenerative medicine. Endonovo’s Immunotronics™ platform is a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation, cell death and the promotion of regeneration. Endonovo’s Cytotronics™ platform provides for a method of expanding and manipulating cells using simulated microgravity and Time-Varying Electromagnetic Fields (TVEMF) for tissue engineering and cell therapies. The Company’s initial concentration is on the treatment of acute and chronic inflammatory conditions of the liver using its proprietary Immunotronics™ platform.

Investors: Sign Up for Email Alerts on Endonovo

Safe Harbor Statement

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” “intend,” and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company’s reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company’s estimates as of the date of the press release, and subsequent events and developments may cause the Company’s estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company’s estimates of its future financial performance as of any date subsequent to the date of this press release.